Filing Flows › Comparisons › VREOF vs AMPH
Vireo Growth vs Amphastar Pharmaceuticals: VREOF and AMPH compared
Vireo Growth is the larger company: $209M of revenue in its latest quarter (Q2 2026) against $208M for Amphastar Pharmaceuticals (Q3 2026). Vireo Growth is growing faster (+335% against +8% a year earlier). Amphastar Pharmaceuticals is more profitable, with an operating margin of 24.5% against -3.0%.
Where the money goes: VREOF and AMPH
Vireo Growth (VREOF) · Q2 2026
Vireo Growth, Q2 2026: revenue $209M (+335% year over year), operating margin -3.0%, net loss $100K, operating cash flow $2.4M. The chart follows the revenue to costs, profit and cash.
Amphastar Pharmaceuticals (AMPH) · Q3 2026
Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart follows the revenue to costs, profit and cash.
| Vireo Growth (VREOF) | Amphastar Pharmaceuticals (AMPH) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $209M | $208M |
| Revenue growth, Y/Y | +335% | +8% |
| Gross margin | — | 48.0% |
| Operating margin | -3.0% | 24.5% |
| Net earnings | −$100K | $37.8M |
| Net margin | 0.0% | 18.2% |
| Operating cash flow | $2.4M | $43.3M |
| Free cash flow | — | $33.4M |
| Market value | — | $1.2B |
| P/E | — | 15.0× |
| Analysts’ mean target | — | $22.50 |
Questions
Which is bigger, Vireo Growth or Amphastar Pharmaceuticals?
Vireo Growth is the larger company: $209M of revenue in its latest quarter (Q2 2026) against $208M for Amphastar Pharmaceuticals (Q3 2026).
Is Vireo Growth or Amphastar Pharmaceuticals growing faster?
Vireo Growth is growing faster (+335% against +8% a year earlier).
Which is more profitable, Vireo Growth or Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals is more profitable, with an operating margin of 24.5% against -3.0%.
More: Vireo Growth earnings · how Vireo Growth makes money · Amphastar Pharmaceuticals earnings · how Amphastar Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.